[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wegro App @wegro_app on x 10.4K followers
Created: 2025-07-19 12:41:17 UTC
Aarti Drugs Limited released its Q1 FY26 Investor Presentation, providing key financial and operational updates. 🗓️
𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▪ Total Revenue: ₹591 crore, a X% increase YoY. ⬆️ ▪ EBITDA: ₹74 crore, reflecting a XX% YoY increase. ▪ PAT: ₹54 crore, a XX% YoY increase. ▪ Gross Profit Margin: 36.8%.
𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗨𝗽𝗱𝗮𝘁𝗲𝘀: ▪ API segment witnessed improved demand. 💊 ▪ Capex of ~₹48.5 crore in Q1FY26, with a total expected capex of ~₹150-200 crore for FY26. ▪ Trial production started at the new greenfield manufacturing facility in Sayakha, Gujarat. 🏭 ▪ Greenfield Salicylic Acid plant at Tarapur is progressing and expected to contribute from Q3 onwards. ▪ US government's high tariffs on Chinese pharmaceutical products create new opportunities for Indian API manufacturers. 🌍 ▪ Oncology facility of formulation subsidiary has got USFDA approval & UKMHRA approval for our OSD facility.
𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: Focused on execution, cost optimization, and product mix enhancement to drive sustainable growth and margin improvement. 🚀
📊 AARTI DRUGS LTD | 🏷️ Investor Presentation
🌐 Details:
⚡️AI-driven WhatsApp updates - Try FREE 👉
XXX engagements
Related Topics investment drugs